Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study for Patients Previously Enrolled in Studies With Pelabresib
2023-508950-24-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of pelabresib in myelofibrosis (MF), thrombocythemia and myeloproliferative disorder (MPD), sponsored by Novartis. Primary endpoints: Occurrence and severity of treatment-emergent adverse events and serious treatment-emergent adverse events, Overall survival and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
pelabresib
03
Conditions
myelofibrosis (MF)thrombocythemiamyeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2023-508950-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508950-24-00.